Dow Jones :A new class of drugs being developed to treat Type 2 diabetes showed the potential to help lower blood glucose levels through a different mechanism than current treatments, according to new studies released at a major diabetes conference.
The most advanced drug in the class, dapagliflozin, is being developed by Bristol-Myers Squibb Co. (BMY) and AstraZeneca PLC (AZN, AZN.LN). The product is designed to lower blood glucose levels in patients with diabetes by increasing the amount of glucose excreted in the urine of people with diabetes. The companies hope to file for U.S. Food and Drug Administration and European Medicines Agency approvals of the product later this year...continue
Posts
No comments:
Post a Comment